Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Subsequent Events

v3.8.0.1
Note 12 - Subsequent Events
6 Months Ended
Dec. 31, 2017
Notes to Financial Statements  
Subsequent Events [Text Block]
Note
12.
Subsequent Events:
 
On
January 2, 2018,
Bio-
Techne acquired Atlanta Biologicals, Inc. and its affiliated company, Scientific Ventures, Inc for approximately
$50
million. The transaction is financed through available cash on hand. Atlanta Biologicals fetal bovine serum (FBS) product line strengthens and complements our current tissue culture reagents offering and furthers our efforts to provide more complete solutions to our research customers
.
The purchase accounting for this acquisition is in progress
.
 
 
On
February 1, 2018
Bio-Techne acquired Eurocell Diagnostics SAS a company based in Rennes, France for approximately $
7.5
million. Eurocell sells directly to the laboratory markets in the French region as well as servicing the EMEA markets via a network of distributors.
The transaction was financed through cash on hand. The purchase accounting for this acquisition is in progress.